HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laura Falasca Selected Research

Enzymes

1/2021Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis.
1/2018Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.
1/2018Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.
4/2003Transglutaminase type II plays a protective role in hepatic injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laura Falasca Research Topics

Disease

5Infections
06/2022 - 01/2003
5COVID-19
06/2022 - 01/2021
2Sepsis (Septicemia)
07/2010 - 02/2008
2Splenomegaly
06/2005 - 06/2003
2Glomerulonephritis
06/2005 - 06/2003
1Angioedema
01/2022
1Macroglossia
01/2022
1Necrosis
03/2021
1Hyperferritinemia
01/2021
1Bacterial Infections (Bacterial Infection)
01/2021
1Bites and Stings (Sting)
01/2021
1Liver Diseases (Liver Disease)
01/2021
1Iron Overload
01/2021
1Disease Progression
01/2018
1Non-alcoholic Fatty Liver Disease
01/2018
1Pneumonia (Pneumonitis)
01/2018
1Carcinogenesis
02/2016
1Neoplasms (Cancer)
12/2015
1Prostatic Neoplasms (Prostate Cancer)
12/2015
1Huntington Disease (Huntington's Disease)
11/2014
1Tuberculosis (Tuberculoses)
09/2012
1Spinocerebellar Ataxias (Spinocerebellar Ataxia)
06/2012
1Neurodegenerative Diseases (Neurodegenerative Disease)
06/2012
1Papillomavirus Infections
06/2011
1Melanoma (Melanoma, Malignant)
04/2011
1Hypertension (High Blood Pressure)
10/2010
1Insulin Resistance
10/2010
1Acute Cholecystitis
10/2010
1Hepatitis
10/2010
1Endotoxemia
02/2008
1Shock
02/2008
1Hyperplasia
06/2003
1Liver Cirrhosis (Hepatic Cirrhosis)
04/2003

Drug/Important Bio-Agent (IBA)

6TransglutaminasesIBA
01/2021 - 06/2005
4EnzymesIBA
01/2021 - 04/2003
3Proteins (Proteins, Gene)FDA Link
02/2016 - 04/2003
2Cysteamine (Mercaptamine)FDA Link
06/2022 - 12/2021
2VaccinesIBA
06/2022 - 09/2012
2Pharmaceutical PreparationsIBA
06/2022 - 12/2021
2Protein Glutamine gamma Glutamyltransferase 2IBA
01/2021 - 01/2003
2AutoantibodiesIBA
06/2005 - 06/2003
1Antihypertensive Agents (Antihypertensives)IBA
01/2022
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2022
1Antiviral Agents (Antivirals)IBA
12/2021
1CystamineIBA
12/2021
1CholesterolIBA
12/2021
1Lipoproteins (Lipoprotein)IBA
12/2021
1CatecholaminesIBA
03/2021
1Ferritins (Ferritin)IBA
01/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2021
1IronIBA
01/2021
1Caveolin 1IBA
01/2019
1ChemokinesIBA
01/2018
1Beclin-1IBA
02/2016
1Biomarkers (Surrogate Marker)IBA
12/2015
1Ataxin-1IBA
06/2012
1polyglutamineIBA
06/2012
1Purinergic Receptors (Receptors, Purine)IBA
08/2011
1Adenosine Triphosphate (ATP)IBA
08/2011
1Oncogene Proteins (Oncogene Protein)IBA
06/2011
1PolyaminesIBA
06/2011
1FenretinideIBA
04/2011
1Bortezomib (Velcade)FDA Link
04/2011
1Hydrochlorothiazide (Esidrix)FDA LinkGeneric
10/2010
1DiureticsIBA
10/2010
1olmesartanIBA
10/2010
1ThiazidesIBA
10/2010
1EndotoxinsIBA
07/2010
1NF-kappa B (NF-kB)IBA
02/2008
1Dexamethasone (Maxidex)FDA LinkGeneric
06/2003
1Antigen-Antibody Complex (Immune Complex)IBA
06/2003

Therapy/Procedure

5Therapeutics
06/2022 - 10/2010